QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:ALZN

Alzamend Neuro (ALZN) Stock Forecast, Price & News

$0.23
0.00 (0.00%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.23
▼
$0.24
50-Day Range
$0.22
▼
$0.52
52-Week Range
$0.21
▼
$1.50
Volume
74,898 shs
Average Volume
194,544 shs
Market Capitalization
$22.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Alzamend Neuro MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
555.3% Upside
$1.50 Price Target
Short Interest
Healthy
0.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

58th out of 961 stocks

Pharmaceutical Preparations Industry

14th out of 448 stocks

See Top Rated MarketRank™ Stocks Here

ALZN stock logo

About Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

ALZN Price History

ALZN Stock News Headlines

September 14, 2023 | americanbankingnews.com
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 60.7% in August
August 30, 2023 | msn.com
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
September 21, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
August 30, 2023 | finance.yahoo.com
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
August 25, 2023 | benzinga.com
Benzinga Neuro
August 24, 2023 | finance.yahoo.com
We're A Little Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
June 28, 2023 | markets.businessinsider.com
Maxim Group Reaffirms Their Buy Rating on Alzamend Neuro (ALZN)
June 24, 2023 | morningstar.com
Alzamend Neuro Inc Ordinary Shares
September 21, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
June 22, 2023 | finance.yahoo.com
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
June 22, 2023 | benzinga.com
EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study
June 13, 2023 | finance.yahoo.com
Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Group’s Virtual Healthcare Conference
April 14, 2023 | benzinga.com
Alzamend Neuro Stock (NASDAQ:ALZN), Dividends
April 12, 2023 | msn.com
Maxim Group Initiates Coverage of Alzamend Neuro (ALZN) with Buy Recommendation
April 3, 2023 | finance.yahoo.com
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 3, 2023 | finance.yahoo.com
EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine
April 3, 2023 | finance.yahoo.com
KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
March 22, 2023 | finance.yahoo.com
EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
March 17, 2023 | finance.yahoo.com
We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully
March 16, 2023 | finance.yahoo.com
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
February 21, 2023 | barrons.com
Alzamend Neuro Inc.
January 26, 2023 | finance.yahoo.com
Alzamend Neuro to Present at Sequire Biotechnology Conference
January 4, 2023 | finance.yahoo.com
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
December 28, 2022 | finance.yahoo.com
EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia
December 28, 2022 | finance.yahoo.com
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
November 22, 2022 | finance.yahoo.com
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
November 15, 2022 | finance.yahoo.com
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
See More Headlines
Receive ALZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter.

ALZN Company Calendar

Last Earnings
9/13/2023
Today
9/21/2023
Next Earnings (Estimated)
12/11/2023
Fiscal Year End
4/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALZN
CUSIP
N/A
CIK
1677077
Web
www.alzamend.com
Phone
844-722-6303
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.50
High Stock Price Forecast
$1.50
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+536.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,880,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-349.69%
Return on Assets
-223.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.88
Quick Ratio
0.88

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
96,940,000
Free Float
86,412,000
Market Cap
$22.83 million
Optionable
Not Optionable
Beta
0.01
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Stephan Jackman (Age 46)
    CEO & Director
    Comp: $434.24k
  • Mr. David J. Katzoff (Age 60)
    Chief Financial Officer
    Comp: $116.67k
  • Mr. Henry C. W. Nisser Esq. (Age 54)
    Exec. VP, Gen. Counsel & Director
  • Mr. Kenneth S. Cragun CPA (Age 62)
    Sr. VP of Fin.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ALZN Stock - Frequently Asked Questions

Should I buy or sell Alzamend Neuro stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alzamend Neuro in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALZN shares.
View ALZN analyst ratings or view top-rated stocks.

What is Alzamend Neuro's stock price forecast for 2023?

1 equities research analysts have issued 12 month price objectives for Alzamend Neuro's stock. Their ALZN share price forecasts range from $1.50 to $1.50. On average, they expect the company's share price to reach $1.50 in the next twelve months. This suggests a possible upside of 536.9% from the stock's current price.
View analysts price targets for ALZN or view top-rated stocks among Wall Street analysts.

How have ALZN shares performed in 2023?

Alzamend Neuro's stock was trading at $0.5649 on January 1st, 2023. Since then, ALZN stock has decreased by 58.3% and is now trading at $0.2355.
View the best growth stocks for 2023 here.

Are investors shorting Alzamend Neuro?

Alzamend Neuro saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 216,000 shares, a decrease of 60.7% from the August 15th total of 549,900 shares. Based on an average trading volume of 187,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.4% of the shares of the stock are sold short.
View Alzamend Neuro's Short Interest.

When is Alzamend Neuro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 11th 2023.
View our ALZN earnings forecast.

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) issued its quarterly earnings data on Wednesday, September, 13th. The company reported ($0.04) earnings per share for the quarter.

When did Alzamend Neuro IPO?

(ALZN) raised $12 million in an IPO on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager.

What is Alzamend Neuro's stock symbol?

Alzamend Neuro trades on the NASDAQ under the ticker symbol "ALZN."

Who are Alzamend Neuro's major shareholders?

Alzamend Neuro's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include David J Katzoff, L Mary Smith, Lynne Fahey Mcgrath, Mark Gustafson, Milton C Ault III, Milton C Ault III, Milton C Ault III and Stephan Jackman.
View institutional ownership trends.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alzamend Neuro's stock price today?

One share of ALZN stock can currently be purchased for approximately $0.24.

How much money does Alzamend Neuro make?

Alzamend Neuro (NASDAQ:ALZN) has a market capitalization of $22.83 million.

How can I contact Alzamend Neuro?

The official website for the company is www.alzamend.com. The company can be reached via phone at 844-722-6303.

This page (NASDAQ:ALZN) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -